Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by wexworthon Nov 28, 2020 7:13am
164 Views
Post# 31993975

RE:Ain't no sunshine

RE:Ain't no sunshine
that's it, we really don't know. if you don't trust them then that becomes a double edge sword. you may not trust them to deliver something by year end, but one should also not trust them that they aren't going to come out with something significant where there is zero time to react. I am holding until next spring or summer when I will re-evaluate as well. So far, they set a list of targets and are systematically checking off the milestones. The part that gets interesting here is that they are left with fewer easy wins which means its a heavier lift to get them out the door, but also significantly different payoff scenarios. I personally am not going to sell for a few pennies advantage only to find out the next day they release something spectacular and be 10, 20 or more cents off that opportunity.
Bullboard Posts